Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gavere – page 95

1 677 clinical trials in Gavere, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gavere at a glance
1 677
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 677 trials in Gavere

Open in trial search

Study of BMS-986446 for Early Alzheimer's Disease Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CX-037231
  • Sponsor:Moderna Inc.

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Radboud universitair medisch centrum Stichting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:QEL-001
  • Sponsor:Quell Therapeutics Limited

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Elafibranor for Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Pharma

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gavere

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and deprescribing strategies for patients with chronic gastrointestinal conditions.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

This primary care-based trial evaluates different approaches to reducing long-term PPI use, including on-demand therapy and alternative treatments with alginate formulations, aiming to establish optimal deprescribing protocols.

02 Primary Care Innovation

Ground-breaking research exploring patient-centered approaches to medication reduction in primary care settings, with a focus on chronic medication management.

  • Medication Optimization
  • Patient-Centered Care
  • Evidence-Based Deprescribing

The study compares different therapeutic strategies to help patients safely reduce their dependence on long-term acid suppression medication.

03 Therapeutic Strategy Comparison

Comprehensive evaluation of three distinct approaches to medication deprescribing, focusing on long-term outcomes and patient safety.

  • Comparative Effectiveness Research
  • Alternative Treatment Methods
  • Safety Monitoring

This research aims to establish evidence-based guidelines for reducing unnecessary long-term medication use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.